Behjatolah Monzavi Karbassi
Sourced from institutional research profiles (UAMS TRI or ARA).
Associate Professor
Pathology, College of Medicine
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Behjatolah Monzavi Karbassi's research focuses on cancer immunotherapy, particularly investigating novel therapeutic targets and strategies to enhance the body's immune response against tumors. His work explores the role of specific molecular pathways and cellular interactions within the tumor microenvironment that influence immune evasion and antitumor efficacy.
Karbassi is the principal investigator on an NIH/National Cancer Institute grant totaling $178,819, which supports his study on targeting scavenger receptor A (SR-A) as a therapeutic approach in breast cancer. This research aims to understand how modulating SR-A can remodel the immune cell populations within tumors, potentially leading to increased CD8-positive T cell activity and improved antitumor outcomes. His publications also address the immunogenicity of carbohydrate mimotopes and synthetic conjugates, the interaction of tumor-associated glycans with macrophages, and the role of specific proteins like CST6 in modulating immunosuppression within the multiple myeloma microenvironment.
Metrics
- Publications: 6
Selected Publications
-
Abstract 2908: SR-A antagonism remodels the myeloid population of tumor immune microenvironment, expands CD8-positive T cells, and enhances antitumor efficacy in vivo (2026)
-
The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment (2024)
-
Harnessing Antibody Polyspecificity for Cancer Immunotherapy (2022)
-
Abstract 1450: Tumor-associated glycans interact with macrophages through class-A scavenger receptor (2016)
-
Evaluating the immunogenicity of carbohydrate mimotopes and synthetic conjugates (2007)
-
Reduction of tumor growth and spontaneous metastasis through induction of carbohydrate cross-reactive apoptotic antibodies (2005)Cancer Research OpenAlex
Federal Grants 1 $178,819 total
Research Interests
My primary research interest is in developing immunotherapeutic strategies to potentiate the anti-cancer immune response by targeting immune suppression within the tumor microenvironment. Central to my approach is the investigation of tumor-associated glycans (TAGs) as therapeutic targets, with a particular emphasis on breast cancer.
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- Mimotope Conversion of HIV-1 Carbohydrate Antigens NIH Co-Investigator
- Vaccination of High-Risk Breast Cancer patients with Carbohydrate Mimicking Peptides US Department of the Army Co-Investigator
- Ex vivo models of breast cancer for the development of novel drug combinations, a pilot study. Arkansas Breast Cancer Research Program Co-Investigator
- Role of scavenger receptor-A (SR-A) binding to tumor-associated glycans Arkansas Breast cancer Research program Co-Investigator
- Defining Tumor-Associated Glycans on Breast Cancer Cells that are Ligands for Macrophage SR-A UAMS Medical Research Endowment fund Principle Investigator
- Explant models and derived primary cell lines for the discovery and testing of novel therapies for breast cancer. Arkansas Breast Cancer Research Program. Co-Investigator
- Vaccination of Breast Cancer Patients with P10s-PADRE Winthrop P Rockefeller Cancer Institute Principle Investigator
- Immune Responses to a Carbohydrate Mimetic Peptide Vaccine UAMS research council, Development Enhancement Awards for Proposals Principle Investigator
- Immune monitoring of vaccinated breast cancer patients Arkansas Bioscience Institute, Principle Investigator
Collaboration Network
Top Collaborators
- Harnessing Antibody Polyspecificity for Cancer Immunotherapy
- Reduction of tumor growth and spontaneous metastasis through induction of carbohydrate cross-reactive apoptotic antibodies
- Abstract 1450: Tumor-associated glycans interact with macrophages through class-A scavenger receptor
- Evaluating the immunogenicity of carbohydrate mimotopes and synthetic conjugates
- Reduction of tumor growth and spontaneous metastasis through induction of carbohydrate cross-reactive apoptotic antibodies
- Evaluating the immunogenicity of carbohydrate mimotopes and synthetic conjugates
- Abstract 2908: SR-A antagonism remodels the myeloid population of tumor immune microenvironment, expands CD8-positive T cells, and enhances antitumor efficacy in vivo
- Reduction of tumor growth and spontaneous metastasis through induction of carbohydrate cross-reactive apoptotic antibodies
- Evaluating the immunogenicity of carbohydrate mimotopes and synthetic conjugates
- Abstract 1450: Tumor-associated glycans interact with macrophages through class-A scavenger receptor
- Abstract 2908: SR-A antagonism remodels the myeloid population of tumor immune microenvironment, expands CD8-positive T cells, and enhances antitumor efficacy in vivo
- Reduction of tumor growth and spontaneous metastasis through induction of carbohydrate cross-reactive apoptotic antibodies
- Reduction of tumor growth and spontaneous metastasis through induction of carbohydrate cross-reactive apoptotic antibodies
- Reduction of tumor growth and spontaneous metastasis through induction of carbohydrate cross-reactive apoptotic antibodies
- Evaluating the immunogenicity of carbohydrate mimotopes and synthetic conjugates
- Evaluating the immunogenicity of carbohydrate mimotopes and synthetic conjugates
- Harnessing Antibody Polyspecificity for Cancer Immunotherapy
- Harnessing Antibody Polyspecificity for Cancer Immunotherapy
- Harnessing Antibody Polyspecificity for Cancer Immunotherapy
- The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment
- The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment
- The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment
Similar Researchers
Based on overlapping research topics